Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.
Lancet Psychiatry – April 05, 2016
Source: PubMed
Summary
Imagine a single therapy session profoundly improving long-standing mental health conditions. Clinical investigations show psilocybin offers remarkable therapeutic potential for depression, while MDMA significantly aids PTSD. Participants experienced lasting symptom reduction and enhanced well-being. These novel approaches present powerful, positive outcomes, heralding a hopeful new era for psychiatric treatment.
Abstract
Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA.